Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
MacroGenics, Inc. (MGNX)
USD4.27
-0.03 (-0.58%)
US NASDAQ Healthcare Biotechnology
Address
9704 Medical Center Drive 20850
Rockville, MD, US
Rockville, MD, US
CEO
Eric Risser
Website
macrogenics.com
IPO
2013-10-10
CIK 1125345 ISIN US5560991094
Description
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company’s product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule that targets an undisclosed antigen expressed across several solid tumors, which is in preclinical trials. It is also developing T-cell engager programs. The company has collaborations with TerSera Therapeutics LLC; Incyte Corporation; and Gilead Sciences, Inc. MacroGenics, Inc. was incorporated in 2000 and is headquartered in Rockville, Maryland.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD4.27
-0.03 (-0.58%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
1M
Beta
1.20
Float Shares
55.59M
Free Float %
87.5%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +19.32% | +18.92% | +1.44% | +105.85% | +120.00% | +118.63% | +128.57% | -46.01% | -87.81% | -79.76% | -85.91% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (22 ratings, all time)
Buy
Price Targets & DCF
Current price
4.27
Low
6.00
+40.7%
Consensus
6.00
+40.7%
Median
6.00
+40.7%
High
6.00
+40.7%
Ratings Trend (MoM)
43% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 2 | 0 |
| Hold | 4 | -1 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | 1 |
6.00
+40.7%
|
| Last Quarter | 1 |
6.00
+40.7%
|
| Last Year | 2 |
4.50
+5.5%
|
| All Time | 15 |
10.20
+139.2%
|
Quality scores
Altman Z-Score
-5.75
Distress
Piotroski F-Score
2 / 9
Weak
MOAT Score
1 / 10
No MOAT
Composite Rating
C-
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+0.8% Q1'26: +57.5% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%-10.3% Q1'26: +10.8% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-69.4% Q1'26: -174.0% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-48.7% Q1'26: +0.0% (vs Q1'25)
-
ROIC Biotechnology: -16.1%— Q1'26: +0.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+0.9% ★ Q1'26: +0.8% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-1.63× Q1'26: -0.27× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 5 Rev. Ana. 5 EPS Ana. |
Dec 2027 3 Rev. Ana. 3 EPS Ana. |
Dec 2028 3 Rev. Ana. 3 EPS Ana. |
Dec 2029 2 Rev. Ana. 1 EPS Ana. |
Dec 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
100.85M
est: 104.86M (-3.8%)
|
86.58M
est: 96.96M (-10.7%)
|
155.52M
est: 157.97M (-1.6%)
|
60.12M
est: 56.81M (+5.8%)
|
62.02M
est: 50.18M (+23.6%)
|
97.76M
est: 76.67M (+27.5%)
|
75.64M
est: 83.89M (-9.8%)
|
150.02M
est: 150.06M (0.0%)
|
57.19M
est: 41.02M (+39.4%)
|
148.34M
est: 166.33M (-10.8%)
|
149.50M
est: 138.85M (+7.7%)
|
105.73M
75.07M – 160.65M
-23.9% YoY
|
98.54M
79.44M – 129.13M
-6.8% YoY
|
148.41M
148.41M – 148.41M
+50.6% YoY
|
183.86M
106.20M – 293.17M
+23.9% YoY
|
253.63M
146.50M – 404.42M
+37.9% YoY
|
| EBITDA |
-17.32M
est: 11.18M (-254.9%)
|
-50.92M
est: -59.54M (+14.5%)
|
-12.40M
est: -21.89M (+43.4%)
|
-162.05M
est: -168.58M (+3.9%)
|
-164.88M
est: -158.58M (-4.0%)
|
-119.10M
est: -130.36M (+8.6%)
|
-190.86M
est: -137.64M (-38.7%)
|
-107.89M
est: -184.13M (+41.4%)
|
2.02M
est: -20.59M (+109.8%)
|
-57.37M
est: -83.49M (+31.3%)
|
-65.67M
est: -69.70M (+5.8%)
|
-53.08M
-80.65M – -37.68M
+23.9% YoY
|
-49.47M
-64.82M – -39.88M
+6.8% YoY
|
-74.50M
-74.50M – -74.50M
-50.6% YoY
|
-92.30M
-147.17M – -53.31M
-23.9% YoY
|
-127.32M
-203.01M – -73.54M
-37.9% YoY
|
| EBIT |
-20.18M
est: 9.28M (-317.4%)
|
-60.04M
est: -65.33M (+8.1%)
|
-22.14M
est: -29.21M (+24.2%)
|
-171.21M
est: -177.91M (+3.8%)
|
-177.19M
est: -206.20M (+14.1%)
|
-131.06M
est: -147.03M (+10.9%)
|
-202.12M
est: -146.40M (-38.1%)
|
-119.76M
est: -196.72M (+39.1%)
|
-7.63M
est: -23.43M (+67.4%)
|
-64.91M
est: -95.02M (+31.7%)
|
-72.84M
est: -79.33M (+8.2%)
|
-60.41M
-91.78M – -42.89M
+23.9% YoY
|
-56.30M
-73.77M – -45.38M
+6.8% YoY
|
-84.79M
-84.79M – -84.79M
-50.6% YoY
|
-105.04M
-167.49M – -60.67M
-23.9% YoY
|
-144.90M
-231.04M – -83.69M
-37.9% YoY
|
| Net Income |
-20.14M
est: 9.31M (-316.3%)
|
-58.53M
est: 2.03B (-102.9%)
|
-19.63M
est: -27.34M (+28.2%)
|
-171.45M
est: -177.66M (+3.5%)
|
-151.81M
est: -171.14M (+11.3%)
|
-129.74M
est: -145.55M (+10.9%)
|
-202.12M
est: -145.85M (-38.6%)
|
-119.76M
est: 7.45M (-1,707.7%)
|
-9.06M
est: -136.37M (+93.4%)
|
-66.97M
est: -70.44M (+4.9%)
|
-74.62M
est: -74.62M (+0.0%)
|
-86.39M
-203.34M – -19.61M
-15.8% YoY
|
-101.82M
-130.14M – -73.49M
-17.9% YoY
|
-167.67M
-211.57M – -61.89M
-64.7% YoY
|
-101.68M
-180.27M – -45.85M
+39.4% YoY
|
-60.84M
-107.86M – -27.43M
+40.2% YoY
|
| SGA |
22.77M
est: 15.66M (+45.3%)
|
29.83M
est: 59.23M (-49.6%)
|
32.65M
est: 24.27M (+34.6%)
|
40.50M
est: 43.30M (-6.5%)
|
46.06M
est: 30.66M (+50.2%)
|
42.74M
est: 55.74M (-23.3%)
|
63.01M
est: 45.70M (+37.9%)
|
58.95M
est: 56.48M (+4.4%)
|
52.19M
est: 23.62M (+120.9%)
|
71.05M
est: 95.79M (-25.8%)
|
39.16M
est: 79.96M (-51.0%)
|
60.89M
43.23M – 92.52M
-23.9% YoY
|
56.75M
45.75M – 74.37M
-6.8% YoY
|
85.47M
85.47M – 85.47M
+50.6% YoY
|
105.88M
61.16M – 168.83M
+23.9% YoY
|
146.06M
84.36M – 232.89M
+37.9% YoY
|
| EPS |
-0.63
est: -0.38 (-63.7%)
|
-1.69
est: -1.57 (-7.8%)
|
-0.54
est: -0.70 (+22.4%)
|
-4.19
est: -4.10 (-2.2%)
|
-3.16
est: -3.73 (+15.4%)
|
-2.25
est: -3.20 (+29.6%)
|
-3.18
est: -3.25 (+2.2%)
|
-1.95
est: -2.03 (+4.1%)
|
-0.15
est: -2.19 (+93.2%)
|
-1.07
est: -1.11 (+3.2%)
|
-1.18
est: -1.09 (-7.9%)
|
-1.52
-3.22 – -0.31
-38.8% YoY
|
-1.61
-2.06 – -1.16
-6.2% YoY
|
-1.98
-3.35 – -0.98
-22.6% YoY
|
-1.61
-2.85 – -0.73
+18.5% YoY
|
-0.96
-1.71 – -0.43
+40.2% YoY
|
Recent Grade Changes (3M)
| Date | Firm | Previous | New Grade | Action |
|---|---|---|---|---|
| 2026-04-20 | Barclays | Overweight | Overweight | Maintain |
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-08 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-07 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-06 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-05 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-04 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-01 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-30 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-24 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-23 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-17 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-16 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-82.38M
OE per share TTM
-1.31
Owner's Yield
-44.22%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
49.3%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
25
Total invested
21.00M
Insider transactions (90d)
0
Beneficial owners (>5%)
39
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 10. | 7.28M | 11.90% | — | 7.28M | — | 7.28M | HC, CO | — | 2022-02-11 | ↗ |
| 2 | 2. | 7.28M | 11.90% | — | 7.28M | — | 7.28M | CO | — | 2022-02-11 | ↗ |
| 3 | Armistice Capital, LLC | 6.09M | 9.91% | — | 6.09M | — | — | IA, OO | Delaware | 2023-02-14 | ↗ |
| 4 | Steven Boyd | 6.09M | 9.91% | — | 6.09M | — | — | HC, IN | United States of America | 2023-02-14 | ↗ |
| 5 | 85-4328500 | 5.64M | 9.10% | 1.96M | — | 5.64M | — | IA | Maryland | 2024-02-14 | ↗ |
| 6 | (1) BlackRock, Inc. | 5.19M | 8.50% | 5.05M | — | 5.19M | — | HC | Delaware | 2022-02-03 | ↗ |
| 7 | Wasatch Advisors, Inc. 87-0319391 | 4.11M | 6.70% | 4.11M | — | 4.11M | — | IA | — | 2022-02-11 | ↗ |
| 8 | RTW Investments, LP | 3.98M | 6.50% | — | 3.98M | — | — | IA, PN | Delaware | 2022-02-14 | ↗ |
| 9 | Roderick Wong | 3.98M | 6.50% | — | 3.98M | — | — | HC, IN | United States | 2022-02-14 | ↗ |
| 10 | The Vanguard Group - 23-1945930 | 3.95M | 6.44% | — | 106.0K | 3.80M | 147.9K | IA | Pennsylvania For | 2022-02-10 | ↗ |
| 11 | Peter Kolchinsky | 3.76M | 6.10% | — | 3.76M | — | 3.76M | HC, IN | United States of America | 2023-10-30 | ↗ |
| 12 | RA Capital Healthcare Fund, L.P. | 3.76M | 6.10% | — | 3.76M | — | 3.76M | PN | Delaware | 2023-10-30 | ↗ |
| 13 | RA Capital Management, L.P. | 3.76M | 6.10% | — | 3.76M | — | 3.76M | IA, PN | Delaware | 2023-10-30 | ↗ |
| 14 | Rajeev Shah | 3.76M | 6.10% | — | 3.76M | — | 3.76M | HC, IN | United States of America | 2023-10-30 | ↗ |
| 15 | GOLDMAN SACHS & CO. LLC | 3.30M | 5.40% | — | 3.30M | — | 3.30M | BD, IA, OO | Delaware | 2022-02-04 | ↗ |
| 16 | THE GOLDMAN SACHS GROUP, INC. | 3.30M | 5.40% | — | 3.30M | — | 3.30M | HC, CO | Delaware | 2022-02-04 | ↗ |
| 17 | Israel A. Englander | 3.21M | 5.10% | — | 3.21M | — | 3.21M | IN | Delaware | 2024-06-04 | ↗ |
| 18 | Millennium Group Management LLC | 3.21M | 5.10% | — | 3.21M | — | 3.21M | OO | Delaware | 2024-06-04 | ↗ |
| 19 | Millennium Management LLC | 3.21M | 5.10% | — | 3.21M | — | 3.21M | OO | Delaware | 2024-06-04 | ↗ |
| 20 | James N. Topper | 3.18M | 5.10% | — | 3.18M | — | 3.18M | IN | Delaware | 2024-11-20 | ↗ |
| 21 | Patrick J. Heron | 3.18M | 5.10% | — | 3.18M | — | 3.18M | IN | Delaware | 2024-11-20 | ↗ |
| 22 | Albert Cha | 2.48M | 3.90% | — | 2.48M | — | 2.48M | IN | Delaware | 2024-11-20 | ↗ |
| 23 | James Brush | 2.48M | 3.90% | — | 2.48M | — | 2.48M | IN | Delaware | 2024-11-20 | ↗ |
| 24 | FHMLSP, L.L.C. | 1.55M | 2.50% | — | 1.55M | — | 1.55M | OO | Delaware | 2024-11-20 | ↗ |
| 25 | FHMLSP, L.P. | 1.55M | 2.50% | — | 1.55M | — | 1.55M | PN | Delaware | 2024-11-20 | ↗ |
| 26 | Frazier Life Sciences Public Fund, L.P. | 1.55M | 2.50% | — | 1.55M | — | 1.55M | PN | Delaware | 2024-11-20 | ↗ |
| 27 | Steven A. Cohen | 1.48M | 4.00% | — | 1.48M | — | 1.48M | IN | Citizenship or place of organization United States | 2021-02-16 | ↗ |
| 28 | Point72 Capital Advisors, Inc. | 1.46M | 4.00% | — | 1.46M | — | 1.46M | CO | Citizenship or place of organization Delaware | 2021-02-16 | ↗ |
| 29 | FHMLSP Overage, L.L.C. | 925.8K | 1.50% | — | 925.8K | — | 925.8K | OO | Delaware | 2024-11-20 | ↗ |
| 30 | FHMLSP Overage, L.P. | 925.8K | 1.50% | — | 925.8K | — | 925.8K | PN | Delaware | 2024-11-20 | ↗ |
| 31 | Frazier Life Sciences Public Overage Fund, L.P. | 925.8K | 1.50% | — | 925.8K | — | 925.8K | PN | Delaware | 2024-11-20 | ↗ |
| 32 | Daniel Estes | 575.2K | 0.90% | — | 575.2K | — | 575.2K | IN | Delaware | 2024-11-20 | ↗ |
| 33 | FHMLS XI, L.L.C. | 575.2K | 0.90% | — | 575.2K | — | 575.2K | OO | Delaware | 2024-11-20 | ↗ |
| 34 | FHMLS XI, L.P. | 575.2K | 0.90% | — | 575.2K | — | 575.2K | PN | Delaware | 2024-11-20 | ↗ |
| 35 | Frazier Life Sciences XI, L.P. | 575.2K | 0.90% | — | 575.2K | — | 575.2K | PN | Delaware | 2024-11-20 | ↗ |
| 36 | FHMLS X, L.L.C. | 125.5K | 0.20% | — | 125.5K | — | 125.5K | OO | Delaware | 2024-11-20 | ↗ |
| 37 | FHMLS X, L.P. | 125.5K | 0.20% | — | 125.5K | — | 125.5K | PN | Delaware | 2024-11-20 | ↗ |
| 38 | Frazier Life Sciences X, L.P. | 125.5K | 0.20% | — | 125.5K | — | 125.5K | PN | Delaware | 2024-11-20 | ↗ |
| 39 | Cubist Systematic Strategies, LLC | 15.4K | 4.00% | — | 15.4K | — | 15.4K | OO | Citizenship or place of organization Delaware | 2021-02-16 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
25
-64 vs prev Q
New positions
6
Closed positions
68
Increased
11
Reduced
7
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | MACQUARIE MANAGEMENT HOLDINGS, INC. | 420.0K +420.0K (+100.0%) | 676.00M +676.0M (+100.0%) | 0.66% +0.664 pp | 0.00% +0.001 pp | USD1.61 +0.0% | 1 qtrs NEW |
| 2 | ARMISTICE CAPITAL, LLC | 6.32M +364.0K (+6.1%) | 10.18M +168.8K (+1.7%) | 10.00% +0.561 pp | 0.12% -0.027 pp | USD6.47 -75.1% | 17 qtrs — |
| 3 | NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | 43.8K +43.5K (+11,970.0%) | 9.98M +10.0M (+1,635,530.7%) | 0.07% +0.069 pp | 0.01% +0.006 pp | USD1.61 +0.0% | 3 qtrs — |
| 4 | VANGUARD GROUP INC | 4.23M +2.7K (+0.1%) | 6.81M -291.3K (-4.1%) | 6.68% -0.006 pp | 0.00% +0.000 pp | USD16.87 -90.5% | 49 qtrs — |
| 5 | RENAISSANCE TECHNOLOGIES LLC | 2.91M +1.2M (+71.0%) | 4.68M +1.8M (+63.8%) | 4.60% +1.905 pp | 0.01% +0.004 pp | USD2.14 -24.8% | 16 qtrs — |
| 6 | ACADIAN ASSET MANAGEMENT LLC | 2.52M +863.0 (+0.0%) | 4.05M -177.0K (-4.2%) | 3.98% -0.005 pp | 0.01% -0.001 pp | USD2.48 -35.1% | 16 qtrs — |
| 7 | MILLENNIUM MANAGEMENT LLC | 1.97M -142.4K (-6.7%) | 3.18M -377.4K (-10.6%) | 3.12% -0.230 pp | 0.00% 0.000 pp | USD3.74 -57.0% | 48 qtrs — |
| 8 | JEFFERIES FINANCIAL GROUP INC. | 1.84M +1.8M (+100.0%) | 2.96M +3.0M (+100.0%) | 2.91% +2.912 pp | 0.02% +0.015 pp | USD1.61 +0.0% | 1 qtrs NEW |
| 9 | BANK OF AMERICA CORP /DE/ | 1.84M +1.6M (+777.4%) | 2.96M +2.6M (+740.9%) | 2.91% +2.575 pp | 0.00% +0.000 pp | USD2.19 -26.5% | 48 qtrs — |
| 10 | WASATCH ADVISORS LP | 1.79M -163.9K (-8.4%) | 2.88M -400.4K (-12.2%) | 2.83% -0.264 pp | 0.02% -0.001 pp | USD7.55 -78.7% | 36 qtrs — |
| 11 | MARSHALL WACE, LLP | 1.28M +655.0K (+104.0%) | 2.07M +1.0M (+95.5%) | 2.03% +1.034 pp | 0.00% +0.001 pp | USD2.33 -30.9% | 8 qtrs — |
| 12 | JANE STREET GROUP, LLC | 1.25M +408.2K (+48.2%) | 2.02M +598.0K (+42.0%) | 1.98% +0.644 pp | 0.00% +0.000 pp | USD3.20 -49.7% | 28 qtrs — |
| 13 | TWO SIGMA ADVISERS, LP | 1.20M +446.4K (+59.6%) | 1.92M +666.3K (+53.0%) | 1.89% +0.704 pp | 0.00% +0.001 pp | USD3.25 -50.5% | 7 qtrs — |
| 14 | BLACKROCK, INC. | 1.15M -386.0K (-25.1%) | 1.86M -729.2K (-28.2%) | 1.82% -0.614 pp | 0.00% +0.000 pp | USD3.29 -51.1% | 6 qtrs — |
| 15 | TWO SIGMA INVESTMENTS, LP | 999.5K +562.4K (+128.7%) | 1.61M +874.8K (+119.1%) | 1.58% +0.888 pp | 0.00% +0.001 pp | USD2.72 -40.8% | 17 qtrs — |
| 16 | JACOBS LEVY EQUITY MANAGEMENT, INC | 901.1K +85.2K (+10.4%) | 1.45M +80.0K (+5.8%) | 1.43% +0.133 pp | 0.01% +0.000 pp | USD3.23 -50.2% | 16 qtrs — |
| 17 | CONNOR, CLARK & LUNN INVESTMENT MANAGEMENT LTD. | 818.8K +108.2K (+15.2%) | 1.32M +124.5K (+10.4%) | 1.29% +0.169 pp | 0.00% 0.000 pp | USD5.70 -71.8% | 10 qtrs — |
| 18 | D. E. SHAW & CO., INC. | 756.6K +534.4K (+240.5%) | 1.22M +844.9K (+226.3%) | 1.20% +0.845 pp | 0.00% +0.001 pp | USD1.57 +2.5% | 7 qtrs — |
| 19 | GEODE CAPITAL MANAGEMENT, LLC | 655.3K -2.2K (-0.3%) | 1.06M -49.6K (-4.5%) | 1.04% -0.005 pp | 0.00% +0.000 pp | USD16.67 -90.3% | 49 qtrs — |
| 20 | GSA CAPITAL PARTNERS LLP | 511.0K +450.2K (+740.5%) | 823.0K +721.0K (+706.9%) | 0.81% +0.712 pp | 0.07% +0.062 pp | USD1.62 -0.6% | 17 qtrs — |
| 21 | AFFINITY ASSET ADVISORS, LLC | 484.3K +484.3K (+100.0%) | 779.7K +779.7K (+100.0%) | 0.77% +0.766 pp | 0.04% +0.044 pp | USD1.61 +0.0% | 1 qtrs NEW |
| 22 | SQUAREPOINT OPS LLC | 312.4K -73.2K (-19.0%) | 503.0K -144.9K (-22.4%) | 0.49% -0.117 pp | 0.00% 0.000 pp | USD1.61 +0.0% | 6 qtrs — |
| 23 | PINNACLE ASSOCIATES LTD | 292.7K -45.4K (-13.4%) | 471.2K -96.8K (-17.0%) | 0.46% -0.073 pp | 0.01% -0.002 pp | USD13.73 -88.3% | 43 qtrs — |
| 24 | UNIVERSAL- BETEILIGUNGS- UND SERVICEGESELLSCHAFT MBH | 300.0K +90.0K (+42.9%) | 468.0K +115.2K (+32.7%) | 0.47% +0.142 pp | 0.00% +0.000 pp | USD1.66 -3.0% | 2 qtrs — |
| 25 | VESTAL POINT CAPITAL, LP | 280.0K +— (+0.0%) | 450.8K -19.6K (-4.2%) | 0.44% -0.001 pp | 0.02% -0.006 pp | USD12.75 -87.4% | 8 qtrs — |
| 26 | STATE STREET CORP | 274.6K +— (+0.0%) | 442.1K -19.2K (-4.2%) | 0.43% -0.001 pp | 0.00% +0.000 pp | USD14.39 -88.8% | 49 qtrs — |
| 27 | QUADRATURE CAPITAL LTD | 265.5K +222.8K (+521.5%) | 427.4K +355.6K (+495.6%) | 0.42% +0.352 pp | 0.00% +0.004 pp | USD1.58 +1.9% | 3 qtrs — |
| 28 | POINT72 ASSET MANAGEMENT, L.P. | 249.2K +249.2K (+100.0%) | 401.1K +401.1K (+100.0%) | 0.39% +0.394 pp | 0.00% +0.000 pp | USD1.61 +0.0% | 1 qtrs NEW |
| 29 | XTX TOPCO LTD | 240.3K +66.4K (+38.2%) | 386.9K +94.7K (+32.4%) | 0.38% +0.105 pp | 0.01% -0.005 pp | USD1.63 -1.2% | 15 qtrs — |
| 30 | AMUNDI | 214.3K +214.3K (+100.0%) | 345.0K +345.0K (+100.0%) | 0.34% +0.339 pp | 0.00% +0.000 pp | USD1.61 +0.0% | 4 qtrs — |
| 31 | MACKENZIE FINANCIAL CORP | 207.9K +207.9K (+100.0%) | 323.7K +323.7K (+100.0%) | 0.33% +0.329 pp | 0.00% +0.000 pp | USD1.61 +0.0% | 1 qtrs NEW |
| 32 | HRT FINANCIAL LP | 190.1K +190.1K (+100.0%) | 306.0K +306.0K (+100.0%) | 0.30% +0.301 pp | 0.00% +0.001 pp | USD1.61 +0.0% | 4 qtrs — |
| 33 | DIMENSIONAL FUND ADVISORS LP | 187.8K -157.8K (-45.7%) | 302.1K -278.8K (-48.0%) | 0.30% -0.250 pp | 0.00% 0.000 pp | USD11.10 -85.5% | 36 qtrs — |
| 34 | GOLDMAN SACHS GROUP INC | 181.7K -77.0K (-29.8%) | 292.5K -142.0K (-32.7%) | 0.29% -0.122 pp | 0.00% +0.000 pp | USD2.81 -42.7% | 46 qtrs — |
| 35 | MORGAN STANLEY | 161.0K -828.2K (-83.7%) | 259.2K -1.4M (-84.4%) | 0.25% -1.312 pp | 0.00% 0.000 pp | USD2.55 -36.9% | 49 qtrs — |
| 36 | CANADA PENSION PLAN INVESTMENT BOARD | 155.2K +155.2K (+100.0%) | 249.9K +249.9K (+100.0%) | 0.25% +0.245 pp | 0.00% +0.000 pp | USD1.61 +0.0% | 1 qtrs NEW |
| 37 | NORTHERN TRUST CORP | 152.7K +1.5K (+1.0%) | 245.8K -8.1K (-3.2%) | 0.24% +0.002 pp | 0.00% +0.000 pp | USD15.95 -89.9% | 49 qtrs — |
| 38 | PANAGORA ASSET MANAGEMENT INC | 150.1K +88.9K (+145.2%) | 241.6K +138.8K (+135.0%) | 0.24% +0.140 pp | 0.00% +0.000 pp | USD1.64 -1.8% | 2 qtrs — |
| 39 | UBS GROUP AG | 119.4K +71.7K (+150.0%) | 192.3K +112.0K (+139.5%) | 0.19% +0.113 pp | 0.00% +0.000 pp | USD3.70 -56.5% | 45 qtrs — |
| 40 | INVESCO LTD. | 111.1K +26.7K (+31.6%) | 178.9K +37.0K (+26.1%) | 0.18% +0.042 pp | 0.00% +0.000 pp | USD3.03 -46.9% | 45 qtrs — |
| 41 | — | 100.0K +— (+0.0%) | 161.0K -7.0K (-4.2%) | 0.16% 0.000 pp | 0.00% 0.000 pp | USD2.45 -34.3% | 7 qtrs — |
| 42 | AMERIPRISE FINANCIAL INC | 92.9K -2.4K (-2.5%) | 149.5K -10.6K (-6.6%) | 0.15% -0.004 pp | 0.00% +0.000 pp | USD4.60 -65.0% | 13 qtrs — |
| 43 | CITADEL ADVISORS LLC | 86.3K +56.5K (+189.6%) | 138.9K +88.9K (+177.5%) | 0.14% +0.089 pp | 0.00% +0.000 pp | USD4.53 -64.5% | 13 qtrs — |
| 44 | BRIDGEWAY CAPITAL MANAGEMENT, LLC | 81.2K -7.5K (-8.5%) | 130.7K -18.3K (-12.3%) | 0.13% -0.012 pp | 0.00% 0.000 pp | USD2.80 -42.5% | 5 qtrs — |
| 45 | IKARIAN CAPITAL, LLC | 74.9K -5.2K (-6.5%) | 120.6K -13.9K (-10.4%) | 0.12% -0.008 pp | 0.01% -0.004 pp | USD14.02 -88.5% | 8 qtrs — |
| 46 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 68.5K -155.3K (-69.4%) | 110.4K -265.6K (-70.6%) | 0.11% -0.246 pp | 0.00% +0.000 pp | USD4.09 -60.6% | 29 qtrs — |
| 47 | LPL FINANCIAL LLC | 65.1K +42.0K (+181.2%) | 104.9K +65.9K (+169.5%) | 0.10% +0.066 pp | 0.00% +0.000 pp | USD3.62 -55.5% | 8 qtrs — |
| 48 | FMR LLC | 62.3K -1.0K (-1.6%) | 100.3K -6.1K (-5.7%) | 0.10% -0.002 pp | 0.00% +0.000 pp | USD2.91 -44.7% | 49 qtrs — |
| 49 | PUBLIC EMPLOYEES RETIREMENT SYSTEM OF OHIO | 42.4K +— (+0.0%) | 68.2K -3.0K (-4.2%) | 0.07% 0.000 pp | 0.00% +0.000 pp | USD2.32 -30.6% | 35 qtrs — |
| 50 | BARCLAYS PLC | 41.4K -57.4K (-58.1%) | 66.6K -258.3K (-79.5%) | 0.07% -0.091 pp | 0.00% 0.000 pp | USD4.40 -63.4% | 49 qtrs — |
| 51 | ALPHACORE CAPITAL LLC | 38.1K +38.1K (+100.0%) | 61.3K +61.3K (+100.0%) | 0.06% +0.060 pp | 0.00% +0.001 pp | USD1.61 +0.0% | 1 qtrs NEW |
| 52 | WALLEYE CAPITAL LLC | 33.2K +8.0K (+31.8%) | 53.4K +11.1K (+26.3%) | 0.05% +0.013 pp | 0.00% +0.000 pp | USD1.31 +22.9% | 8 qtrs — |
| 53 | SEI INVESTMENTS CO | 31.3K +— (+0.0%) | 50.4K -2.2K (-4.2%) | 0.05% 0.000 pp | 0.00% +0.000 pp | USD1.27 +26.8% | 4 qtrs — |
| 54 | RANGELEY CAPITAL, LLC | 30.2K +— (+0.0%) | 48.7K -2.1K (-4.2%) | 0.05% 0.000 pp | 0.04% -0.004 pp | USD1.26 +27.8% | 3 qtrs — |
| 55 | XML FINANCIAL, LLC | 25.3K -7.0K (-21.6%) | 40.8K -13.5K (-24.9%) | 0.04% -0.011 pp | 0.00% -0.001 pp | USD4.84 -66.7% | 17 qtrs — |
| 56 | PRUDENTIAL FINANCIAL INC | 22.6K +800.0 (+3.7%) | 36.4K -238.0 (-0.6%) | 0.04% +0.001 pp | 0.00% +0.000 pp | USD1.31 +22.9% | 4 qtrs — |
| 57 | BOOTHBAY FUND MANAGEMENT, LLC | 18.3K -5.2K (-22.0%) | 29.5K -10.0K (-25.3%) | 0.03% -0.008 pp | 0.00% 0.000 pp | USD14.02 -88.5% | 8 qtrs — |
| 58 | EVERCORE WEALTH MANAGEMENT, LLC | 17.5K +— (+0.0%) | 28.2K -1.2K (-4.2%) | 0.03% +0.000 pp | 0.00% +0.000 pp | USD21.19 -92.4% | 47 qtrs — |
| 59 | TUDOR INVESTMENT CORP ET AL | 16.4K +— (+0.0%) | 26.5K -1.2K (-4.2%) | 0.03% +0.000 pp | 0.00% +0.000 pp | USD2.62 -38.5% | 6 qtrs — |
| 60 | R SQUARED LTD | 15.9K +15.9K (+100.0%) | 25.6K +25.6K (+100.0%) | 0.03% +0.025 pp | 0.01% +0.012 pp | USD1.61 +0.0% | 1 qtrs NEW |
| 61 | VANGUARD PERSONALIZED INDEXING MANAGEMENT, LLC | 12.8K +2.2K (+20.8%) | 20.6K +2.8K (+15.8%) | 0.02% +0.004 pp | 0.00% +0.000 pp | USD1.67 -3.6% | 2 qtrs — |
| 62 | CI PRIVATE WEALTH, LLC | 11.8K -2.8K (-19.2%) | 19.0K -5.5K (-22.5%) | 0.02% -0.005 pp | 0.00% +0.000 pp | USD1.68 -4.2% | 2 qtrs — |
| 63 | SOUND INCOME STRATEGIES, LLC | 7.3K +— (+0.0%) | 12.5K -218.0 (-1.7%) | 0.01% +0.000 pp | 0.00% 0.000 pp | USD11.33 -85.8% | 8 qtrs — |
| 64 | ADVISOR GROUP HOLDINGS, INC. | 6.5K -15.0 (-0.2%) | 10.4K -928.0 (-8.2%) | 0.01% +0.000 pp | 0.00% +0.000 pp | USD4.30 -62.6% | 24 qtrs — |
| 65 | JPMORGAN CHASE & CO | 5.8K -749.5K (-99.2%) | 9.3K -1.3M (-99.3%) | 0.01% -1.187 pp | 0.00% 0.000 pp | USD3.19 -49.5% | 49 qtrs — |
| 66 | SIMPLEX TRADING, LLC | 5.1K -2.0K (-28.5%) | 8.2K -2.8K (-25.4%) | 0.01% -0.003 pp | 0.00% +0.000 pp | USD1.35 +19.3% | 3 qtrs — |
| 67 | WELLS FARGO & COMPANY/MN | 3.0K +— (+0.0%) | 4.8K -210.0 (-4.2%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD2.47 -34.8% | 48 qtrs — |
| 68 | CAITONG INTERNATIONAL ASSET MANAGEMENT CO., LTD | 1.5K +1.3K (+1,000.8%) | 2.4K +2.1K (+957.0%) | 0.00% +0.002 pp | 0.00% +0.000 pp | USD1.62 -0.6% | 2 qtrs — |
| 69 | RUSSELL INVESTMENTS GROUP, LTD. | 1.3K -47.8K (-97.4%) | 2.1K -83.8K (-97.6%) | 0.00% -0.076 pp | 0.00% 0.000 pp | USD1.36 +18.4% | 24 qtrs — |
| 70 | IMG WEALTH MANAGEMENT, INC. | 1.2K +— (+0.0%) | 1.9K -80.0 (-4.1%) | 0.00% +0.000 pp | 0.00% 0.000 pp | USD3.25 -50.5% | 5 qtrs — |
| 71 | TRUVESTMENTS CAPITAL LLC | 1.0K +— (+0.0%) | 1.6K -70.0 (-4.1%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD3.26 -50.6% | 6 qtrs — |
| 72 | TOWER RESEARCH CAPITAL LLC (TRC) | 978.00 -15.8K (-94.2%) | 1.6K -26.6K (-94.4%) | 0.00% -0.025 pp | 0.00% -0.001 pp | USD1.83 -12.0% | 23 qtrs — |
| 73 | BNP PARIBAS ARBITRAGE, SNC | 694.00 -86.0K (-99.2%) | 1.1K -144.5K (-99.2%) | 0.00% -0.136 pp | 0.00% 0.000 pp | USD3.19 -49.5% | 46 qtrs — |
| 74 | SPIRE WEALTH MANAGEMENT | 664.00 +— (+0.0%) | 1.1K -47.0 (-4.2%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD5.36 -70.0% | 10 qtrs — |
| 75 | CORNERSTONE PLANNING GROUP LLC | 560.00 +— (+0.0%) | 1.0K +115.0 (+12.9%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD4.30 -62.6% | 7 qtrs — |
| 76 | ROYAL BANK OF CANADA | 879.00 +404.0 (+85.1%) | 1.0K +— (+0.0%) | 0.00% +0.001 pp | 0.00% +0.000 pp | USD1.65 -2.4% | 2 qtrs — |
| 77 | HIGHMARK WEALTH MANAGEMENT LLC | 400.00 +— (+0.0%) | 644.00 -28.0 (-4.2%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD10.88 -85.2% | 25 qtrs — |
| 78 | NISA INVESTMENT ADVISORS, LLC | 347.00 -152.0 (-30.5%) | 559.00 -279.0 (-33.3%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD6.02 -73.3% | 26 qtrs — |
| 79 | LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS LLP/MA | 213.00 +— (+0.0%) | 392.00 +2.0 (+0.5%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD6.71 -76.0% | 13 qtrs — |
| 80 | CLEAR STREET MARKETS LLC | 124.00 +124.0 (+100.0%) | 200.00 +200.0 (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.60 +0.6% | 3 qtrs — |
| 81 | FARMERS & MERCHANTS INVESTMENTS INC | 80.00 +— (+0.0%) | 129.00 -5.0 (-3.7%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD6.70 -76.0% | 13 qtrs — |
| 82 | SBI SECURITIES CO., LTD. | 59.00 -3.0K (-98.1%) | 95.00 -5.0K (-98.2%) | 0.00% -0.005 pp | 0.00% 0.000 pp | USD3.22 -50.0% | 5 qtrs — |
| 83 | SRS CAPITAL ADVISORS, INC. | 55.00 +46.0 (+511.1%) | 89.00 +74.0 (+493.3%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.62 -0.6% | 2 qtrs — |
| 84 | COMERICA BANK | 44.00 +— (+0.0%) | 71.00 -3.0 (-4.1%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD3.25 -50.5% | 8 qtrs — |
| 85 | JONES FINANCIAL COMPANIES LLLP | 30.00 +— (+0.0%) | 48.00 -4.0 (-7.7%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD3.23 -50.2% | 5 qtrs — |
| 86 | ROCKEFELLER CAPITAL MANAGEMENT L.P. | 25.00 +— (+0.0%) | 40.00 -2.0 (-4.8%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.68 -4.2% | 2 qtrs — |
| 87 | INSPIRE INVESTING, LLC | 14.00 +14.0 (+100.0%) | 23.00 +23.0 (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.57 +2.5% | 1 qtrs NEW |
| 88 | OPTIVER HOLDING B.V. | — -2.0 (-100.0%) | — -3.0 (-100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 89 | MACQUARIE GROUP LTD | — -420.0K (-100.0%) | — -706.0K (-100.0%) | 0.00% -0.665 pp | 0.00% -0.001 pp | USD— | 40 qtrs SOLD |
| 90 | SG AMERICAS SECURITIES, LLC | — -17.2K (-100.0%) | — -29.0K (-100.0%) | 0.00% -0.027 pp | 0.00% 0.000 pp | USD— | 6 qtrs SOLD |
| 91 | CRESSET ASSET MANAGEMENT, LLC | — -25.8K (-100.0%) | — -43.4K (-100.0%) | 0.00% -0.041 pp | 0.00% 0.000 pp | USD— | 6 qtrs SOLD |
| 92 | ALGERT GLOBAL LLC | — -88.1K (-100.0%) | — -148.0K (-100.0%) | 0.00% -0.140 pp | 0.00% -0.003 pp | USD— | 2 qtrs SOLD |
| 93 | TWO SIGMA SECURITIES, LLC | — -13.7K (-100.0%) | — -23.0K (-100.0%) | 0.00% -0.022 pp | 0.00% -0.003 pp | USD— | 2 qtrs SOLD |
| 94 | TANG CAPITAL MANAGEMENT LLC | — -218.9K (-100.0%) | — -367.7K (-100.0%) | 0.00% -0.347 pp | 0.00% -0.014 pp | USD— | 7 qtrs SOLD |
| 95 | MANCHESTER CAPITAL MANAGEMENT LLC | — -1.2K (-100.0%) | — -2.1K (-100.0%) | 0.00% -0.002 pp | 0.00% 0.000 pp | USD— | 7 qtrs SOLD |
| 96 | FRAZIER LIFE SCIENCES MANAGEMENT, L.P. | — -3.2M (-100.0%) | — -5.3M (-100.0%) | 0.00% -5.030 pp | 0.00% -0.160 pp | USD— | 14 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 46 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Invesco NASDAQ Future Gen 200 ETF QQQS | 0.52% | 114.2K | 0.20% |
| 2 | ALPS Medical Breakthroughs ETF SBIO | 0.14% | 300.5K | 0.50% |
| 3 | iShares Micro-Cap ETF IWC | 0.06% | 914.3K | 0.60% |
| 4 | iShares Healthcare Innovation UCITS ETF HEAL.L | 0.03% | 323.6K | 0.40% |
| 5 | Goldman Sachs ActiveBeta U.S. Small Cap Equity ETF GSSC | 0.03% | 272.9K | 0.20% |
| 6 | iShares Russell 2000 Growth ETF IWO | 0.01% | 2.23M | 0.24% |
| 7 | Xtrackers Russell 2000 UCITS ETF 1C XRSU.L | 0.01% | 277.2K | 0.30% |
| 8 | Fidelity Enhanced Small Cap ETF FESM | 0.01% | 520.2K | 0.28% |
| 9 | Invesco Russell 2000 UCITS ETF RTYS.L | 0.01% | 27.7K | 0.25% |
| 10 | Global X - Russell 2000 ETF RSSL | 0.01% | 126.6K | 0.08% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.84
Neutral
Ratio by volume
3.00
Bullish
Buys
32
Sells
38
Shares acquired
1.75M
Shares disposed
262.7K
Cash buys
—
Cash sales
—
Net activity
+1,485,088
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-02-15 | Spitznagel Thomas | Officer | M-Exempt | A | Common Stock | 13,332 | 0.00 | — | 44,063 | D | ↗ |
| 2026-02-15 | Smith Beth Ann | Officer | M-Exempt | D | Restricted Stock Unit | 1,095 | 0.00 | — | 0 | D | ↗ |
| 2026-02-15 | Risser Eric Blasius | Director / Officer | M-Exempt | A | Common Stock | 16,665 | 0.00 | — | 83,602 | D | ↗ |
| 2026-02-15 | Peters Jeffrey Stuart | Officer | M-Exempt | D | Restricted Stock Unit | 13,332 | 0.00 | — | 0 | D | ↗ |
| 2026-02-15 | Koenig Scott | Director | M-Exempt | A | Common Stock | 21,165 | 0.00 | — | 867,240 | D | ↗ |
| 2026-02-15 | Karrels James | Officer | M-Exempt | D | Restricted Stock Unit | 14,999 | 0.00 | — | 0 | D | ↗ |
| 2026-02-15 | Bonvini Ezio | Officer | M-Exempt | D | Restricted Stock Unit | 16,665 | 0.00 | — | 0 | D | ↗ |
| 2026-02-12 | Spitznagel Thomas | Officer | A-Award | A | Restricted Stock Unit | 25,000 | 0.00 | — | 25,000 | D | ↗ |
| 2026-02-12 | Smith Beth Ann | Officer | A-Award | A | Restricted Stock Unit | 15,625 | 0.00 | — | 15,625 | D | ↗ |
| 2026-02-12 | Risser Eric Blasius | Director / Officer | A-Award | A | Restricted Stock Unit | 100,000 | 0.00 | — | 100,000 | D | ↗ |
| 2026-02-12 | Peters Jeffrey Stuart | Officer | A-Award | A | Restricted Stock Unit | 25,000 | 0.00 | — | 25,000 | D | ↗ |
| 2026-02-12 | Karrels James | Officer | A-Award | A | Restricted Stock Unit | 25,000 | 0.00 | — | 25,000 | D | ↗ |
| 2026-02-12 | Bonvini Ezio | Officer | A-Award | A | Employee Stock Option (right to buy) | 187,500 | 1.71 | 320.6K | 187,500 | D | ↗ |
| 2026-02-08 | Spitznagel Thomas | Officer | F-InKind | D | Common Stock | 3,186 | 1.81 | 5.8K | 30,731 | D | ↗ |
| 2026-02-08 | Smith Beth Ann | Officer | M-Exempt | D | Restricted Stock Unit | 1,583 | 0.00 | — | 1,584 | D | ↗ |
| 2026-02-08 | Risser Eric Blasius | Director / Officer | F-InKind | D | Common Stock | 4,311 | 1.81 | 7.8K | 66,937 | D | ↗ |
| 2026-02-08 | Peters Jeffrey Stuart | Officer | M-Exempt | D | Restricted Stock Unit | 8,999 | 0.00 | — | 9,000 | D | ↗ |
| 2026-02-08 | Koenig Scott | Director | M-Exempt | A | Common Stock | 15,831 | 0.00 | — | 846,075 | D | ↗ |
| 2026-02-08 | Karrels James | Officer | M-Exempt | A | Common Stock | 9,999 | 0.00 | — | 200,688 | D | ↗ |
| 2026-02-08 | Bonvini Ezio | Officer | F-InKind | D | Common Stock | 4,311 | 1.81 | 7.8K | 135,567 | D | ↗ |
| 2026-02-07 | Spitznagel Thomas | Officer | M-Exempt | A | Common Stock | 6,001 | 0.00 | — | 27,403 | D | ↗ |
| 2026-02-07 | Smith Beth Ann | Officer | M-Exempt | D | Restricted Stock Unit | 2,617 | 0.00 | — | 5,233 | D | ↗ |
| 2026-02-07 | Risser Eric Blasius | Director / Officer | M-Exempt | D | Restricted Stock Unit | 6,668 | 0.00 | — | 13,332 | D | ↗ |
| 2026-02-07 | Peters Jeffrey Stuart | Officer | M-Exempt | D | Restricted Stock Unit | 6,001 | 0.00 | — | 11,999 | D | ↗ |
| 2026-02-07 | Karrels James | Officer | M-Exempt | D | Restricted Stock Unit | 6,334 | 0.00 | — | 12,666 | D | ↗ |
| 2026-02-07 | Bonvini Ezio | Officer | M-Exempt | D | Restricted Stock Unit | 7,001 | 0.00 | — | 13,999 | D | ↗ |
| 2025-12-08 | Smith Beth Ann | Officer | A-Award | A | Employee Stock Option (right to buy) | 25,000 | 1.33 | 33.3K | 25,000 | D | ↗ |
| 2025-08-20 | HEIDEN WILLIAM K | Director | P-Purchase | A | Common Stock | 49,500 | 1.49 | 73.8K | 111,000 | D | ↗ |
| 2025-08-19 | HEIDEN WILLIAM K | Director | P-Purchase | A | Common Stock | 50,500 | 1.52 | 76.8K | 61,500 | D | ↗ |
| 2025-08-15 | Spitznagel Thomas | Officer | A-Award | A | Employee Stock Option (right to buy) | 30,000 | 1.58 | 47.4K | 30,000 | D | ↗ |
| 2025-08-15 | Peters Jeffrey Stuart | Officer | A-Award | A | Employee Stock Option (right to buy) | 30,000 | 1.58 | 47.4K | 30,000 | D | ↗ |
| 2025-08-13 | Risser Eric Blasius | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 550,000 | 1.66 | 913.0K | 550,000 | D | ↗ |
| 2025-08-13 | Koenig Scott | Director | M-Exempt | A | Common Stock | 21,165 | 0.00 | — | 798,580 | D | ↗ |
| 2025-05-21 | STUMP DAVID C | Director | A-Award | A | Stock Option (right to buy) | 22,000 | 1.49 | 32.8K | 22,000 | D | ↗ |
| 2025-05-21 | SIEGEL JAY PHILIP | Director | A-Award | A | Stock Option (right to buy) | 22,000 | 1.49 | 32.8K | 22,000 | D | ↗ |
| 2025-05-21 | O'Brien Federica F. | Director | A-Award | A | Restricted Stock Unit | 3,750 | 0.00 | — | 3,750 | D | ↗ |
| 2025-05-21 | Liu Margaret | Director | A-Award | A | Stock Option (right to buy) | 22,000 | 1.49 | 32.8K | 22,000 | D | ↗ |
| 2025-05-21 | Jackson Scott Thomas | Director | A-Award | A | Restricted Stock Unit | 3,750 | 0.00 | — | 3,750 | D | ↗ |
| 2025-05-21 | HURWITZ EDWARD | Director | A-Award | A | Restricted Stock Unit | 3,750 | 0.00 | — | 3,750 | D | ↗ |
| 2025-05-21 | HEIDEN WILLIAM K | Director | A-Award | A | Stock Option (right to buy) | 22,000 | 1.49 | 32.8K | 22,000 | D | ↗ |
| 2025-05-21 | Ferrante Karen Jean | Director | A-Award | A | Stock Option (right to buy) | 22,000 | 1.49 | 32.8K | 22,000 | D | ↗ |
| 2025-05-21 | Chhabra Meenu | Director | A-Award | A | Stock Option (right to buy) | 22,000 | 1.49 | 32.8K | 22,000 | D | ↗ |
| 2025-05-20 | STUMP DAVID C | Director | M-Exempt | D | Restricted Stock Unit | 6,500 | 0.00 | — | 0 | D | ↗ |
| 2025-05-20 | SIEGEL JAY PHILIP | Director | M-Exempt | D | Restricted Stock Unit | 6,500 | 0.00 | — | 0 | D | ↗ |
| 2025-05-20 | O'Brien Federica F. | Director | M-Exempt | D | Restricted Stock Unit | 6,500 | 0.00 | — | 0 | D | ↗ |
| 2025-05-20 | Liu Margaret | Director | M-Exempt | D | Restricted Stock Unit | 6,500 | 0.00 | — | 0 | D | ↗ |
| 2025-05-20 | Jackson Scott Thomas | Director | M-Exempt | A | Common Stock | 6,500 | 0.00 | — | 11,000 | D | ↗ |
| 2025-05-20 | HURWITZ EDWARD | Director | M-Exempt | D | Restricted Stock Unit | 6,500 | 0.00 | — | 0 | D | ↗ |
| 2025-05-20 | HEIDEN WILLIAM K | Director | M-Exempt | D | Restricted Stock Unit | 6,500 | 0.00 | — | 0 | D | ↗ |
| 2025-05-20 | Ferrante Karen Jean | Director | M-Exempt | D | Restricted Stock Unit | 6,500 | 0.00 | — | 0 | D | ↗ |
| 2025-05-20 | Chhabra Meenu | Director | M-Exempt | D | Restricted Stock Unit | 6,500 | 0.00 | — | 0 | D | ↗ |
| 2025-02-15 | Spitznagel Thomas | Officer | F-InKind | D | Common Stock | 5,520 | 2.56 | 14.1K | 21,402 | D | ↗ |
| 2025-02-15 | Smith Beth Ann | Officer | M-Exempt | A | Common Stock | 1,095 | 0.00 | — | 9,955 | D | ↗ |
| 2025-02-15 | Risser Eric Blasius | Officer | M-Exempt | D | Restricted Stock Unit | 16,665 | 0.00 | — | 16,665 | D | ↗ |
| 2025-02-15 | Peters Jeffrey Stuart | Officer | M-Exempt | D | Restricted Stock Unit | 13,332 | 0.00 | — | 13,332 | D | ↗ |
| 2025-02-15 | Koenig Scott | Director / Officer | M-Exempt | D | Restricted Stock Unit | 42,329 | 0.00 | — | 42,330 | D | ↗ |
| 2025-02-15 | Karrels James | Officer | M-Exempt | D | Restricted Stock Unit | 14,998 | 0.00 | — | 14,999 | D | ↗ |
| 2025-02-15 | Eck Stephen L. | Officer | M-Exempt | A | Common Stock | 16,665 | 0.00 | — | 34,319 | D | ↗ |
| 2025-02-15 | Bonvini Ezio | Officer | M-Exempt | D | Restricted Stock Unit | 16,665 | 0.00 | — | 16,665 | D | ↗ |
| 2025-02-08 | Spitznagel Thomas | Officer | M-Exempt | D | Restricted Stock Unit | 9,001 | 0.00 | — | 17,999 | D | ↗ |
| 2025-02-08 | Smith Beth Ann | Officer | M-Exempt | A | Common Stock | 1,583 | 0.00 | — | 9,472 | D | ↗ |
| 2025-02-08 | Risser Eric Blasius | Officer | M-Exempt | D | Restricted Stock Unit | 11,168 | 0.00 | — | 22,332 | D | ↗ |
| 2025-02-08 | Peters Jeffrey Stuart | Officer | M-Exempt | A | Common Stock | 9,001 | 0.00 | — | 9,001 | D | ↗ |
| 2025-02-08 | Koenig Scott | Director / Officer | M-Exempt | D | Restricted Stock Unit | 31,673 | 0.00 | — | 63,327 | D | ↗ |
| 2025-02-08 | Karrels James | Officer | F-InKind | D | Common Stock | 3,861 | 2.60 | 10.0K | 177,593 | D | ↗ |
| 2025-02-08 | Eck Stephen L. | Officer | M-Exempt | D | Restricted Stock Unit | 11,168 | 0.00 | — | 22,332 | D | ↗ |
| 2025-02-08 | Bonvini Ezio | Officer | M-Exempt | D | Restricted Stock Unit | 11,168 | 0.00 | — | 22,332 | D | ↗ |
| 2025-02-07 | Spitznagel Thomas | Officer | A-Award | A | Restricted Stock Unit | 18,000 | 0.00 | — | 18,000 | D | ↗ |
| 2025-02-07 | Smith Beth Ann | Officer | A-Award | A | Restricted Stock Unit | 7,850 | 0.00 | — | 7,850 | D | ↗ |
| 2025-02-07 | Risser Eric Blasius | Officer | A-Award | A | Restricted Stock Unit | 20,000 | 0.00 | — | 20,000 | D | ↗ |
| 2025-02-07 | Peters Jeffrey Stuart | Officer | A-Award | A | Restricted Stock Unit | 18,000 | 0.00 | — | 18,000 | D | ↗ |
| 2025-02-07 | Karrels James | Officer | A-Award | A | Restricted Stock Unit | 19,000 | 0.00 | — | 19,000 | D | ↗ |
| 2025-02-07 | Eck Stephen L. | Officer | A-Award | A | Employee Stock Option (right to buy) | 113,000 | 2.60 | 293.8K | 113,000 | D | ↗ |
| 2025-02-07 | Bonvini Ezio | Officer | A-Award | A | Employee Stock Option (right to buy) | 128,000 | 2.60 | 332.8K | 128,000 | D | ↗ |
| 2025-01-02 | Smith Beth Ann | Officer | — | — | Employee Stock Option (right to buy) | 5,000 | 19.18 | 95.9K | 0 | D | ↗ |
| 2024-10-07 | Koenig Scott | Director / Officer | G-Gift | A | Common Stock | 53,265 | 0.00 | — | 427,480 | I | ↗ |
| 2024-09-23 | Koenig Scott | Director / Officer | G-Gift | D | Common Stock | 374,215 | 0.00 | — | 703,413 | D | ↗ |
| 2024-05-21 | STUMP DAVID C | Director | A-Award | A | Restricted Stock Unit | 6,500 | 0.00 | — | 6,500 | — | ↗ |
| 2024-05-21 | SIEGEL JAY PHILIP | Director | A-Award | A | Stock Option (right to buy) | 16,500 | 4.26 | 70.3K | 16,500 | — | ↗ |
| 2024-05-21 | O'Brien Federica F. | Director | A-Award | A | Restricted Stock Unit | 6,500 | 0.00 | — | 6,500 | — | ↗ |
| 2024-05-21 | Liu Margaret | Director | A-Award | A | Restricted Stock Unit | 6,500 | 0.00 | — | 6,500 | — | ↗ |
| 2024-05-21 | Jackson Scott Thomas | Director | A-Award | A | Stock Option (right to buy) | 16,500 | 4.26 | 70.3K | 16,500 | — | ↗ |
| 2024-05-21 | HURWITZ EDWARD | Director | A-Award | A | Restricted Stock Unit | 6,500 | 0.00 | — | 6,500 | — | ↗ |
| 2024-05-21 | HEIDEN WILLIAM K | Director | A-Award | A | Restricted Stock Unit | 6,500 | 0.00 | — | 6,500 | — | ↗ |
| 2024-05-21 | Ferrante Karen Jean | Director | A-Award | A | Stock Option (right to buy) | 16,500 | 4.26 | 70.3K | 16,500 | — | ↗ |
| 2024-05-21 | Chhabra Meenu | Director | A-Award | A | Stock Option (right to buy) | 16,500 | 4.26 | 70.3K | 16,500 | — | ↗ |
| 2024-05-20 | STUMP DAVID C | Director | M-Exempt | D | Restricted Stock Unit | 4,500 | 0.00 | — | 0 | — | ↗ |
| 2024-05-20 | SIEGEL JAY PHILIP | Director | M-Exempt | D | Restricted Stock Unit | 4,500 | 0.00 | — | 0 | — | ↗ |
| 2024-05-20 | O'Brien Federica F. | Director | M-Exempt | D | Restricted Stock Unit | 4,500 | 0.00 | — | 0 | — | ↗ |
| 2024-05-20 | Liu Margaret | Director | M-Exempt | D | Restricted Stock Unit | 4,500 | 0.00 | — | 0 | — | ↗ |
| 2024-05-20 | Jackson Scott Thomas | Director | M-Exempt | D | Restricted Stock Unit | 4,500 | 0.00 | — | 0 | — | ↗ |
| 2024-05-20 | HURWITZ EDWARD | Director | M-Exempt | D | Restricted Stock Unit | 4,500 | 0.00 | — | 0 | — | ↗ |
| 2024-05-20 | HEIDEN WILLIAM K | Director | M-Exempt | D | Restricted Stock Unit | 4,500 | 0.00 | — | 0 | — | ↗ |
| 2024-05-20 | Ferrante Karen Jean | Director | M-Exempt | D | Restricted Stock Unit | 4,500 | 0.00 | — | 0 | — | ↗ |
| 2024-05-20 | Chhabra Meenu | Director | M-Exempt | D | Restricted Stock Unit | 4,500 | 0.00 | — | 0 | — | ↗ |
| 2024-04-04 | Peters Jeffrey Stuart | Officer | S-Sale | D | Common Stock | 147 | 15.51 | 2.3K | 8,748 | — | ↗ |
| 2024-03-06 | Peters Jeffrey Stuart | Officer | M-Exempt | D | Employee stock option (right to buy) | 8,750 | 10.15 | 88.8K | 39,375 | — | ↗ |
| 2024-03-04 | Spitznagel Thomas | Officer | M-Exempt | D | Employee stock option (right to buy) | 10,000 | 11.50 | 115.0K | 77,000 | — | ↗ |
| 2024-03-04 | Risser Eric Blasius | Officer | M-Exempt | D | Employee stock option (right to buy) | 15,000 | 10.15 | 152.3K | 155,000 | — | ↗ |
| 2024-03-04 | Karrels James | Officer | S-Sale | D | Common Stock | 30,000 | 20.50 | 615.0K | 171,452 | — | ↗ |
| 2024-02-26 | Peters Jeffrey Stuart | Officer | S-Sale | D | Common Stock | 16,124 | 17.22 | 277.7K | 8,895 | — | ↗ |
| 2024-02-22 | Peters Jeffrey Stuart | Officer | F-InKind | D | Common Stock | 10,126 | 17.11 | 173.3K | 25,019 | — | ↗ |
| 2024-02-22 | Bonvini Ezio | Officer | M-Exempt | A | Common Stock | 28,125 | 0.00 | — | 110,258 | — | ↗ |
| 2024-02-15 | Spitznagel Thomas | Officer | M-Exempt | D | Restricted Stock Unit | 13,336 | 0.00 | — | 26,664 | — | ↗ |
| 2024-02-15 | Risser Eric Blasius | Officer | M-Exempt | A | Common Stock | 16,670 | 0.00 | — | 70,938 | — | ↗ |
| 2024-02-15 | Peters Jeffrey Stuart | Officer | F-InKind | D | Common Stock | 4,441 | 17.40 | 77.3K | 8,895 | — | ↗ |
| 2024-02-15 | Koenig Scott | Director / Officer | M-Exempt | A | Common Stock | 42,341 | 0.00 | — | 1,091,977 | — | ↗ |
| 2024-02-15 | Karrels James | Officer | M-Exempt | A | Common Stock | 15,003 | 0.00 | — | 206,779 | — | ↗ |
| 2024-02-15 | Eck Stephen L. | Officer | M-Exempt | D | Restricted Stock Unit | 16,670 | 0.00 | — | 33,330 | — | ↗ |
| 2024-02-15 | Cilinski Lynn | Officer | F-InKind | D | Common Stock | 2,378 | 17.40 | 41.4K | 6,213 | — | ↗ |
| 2024-02-15 | Bonvini Ezio | Officer | M-Exempt | A | Common Stock | 16,670 | 0.00 | — | 88,004 | — | ↗ |
| 2024-02-08 | Spitznagel Thomas | Officer | A-Award | A | Restricted Stock Unit | 27,000 | 0.00 | — | 27,000 | — | ↗ |
| 2024-02-08 | Risser Eric Blasius | Officer | A-Award | A | Restricted Stock Unit | 33,500 | 0.00 | — | 33,500 | — | ↗ |
| 2024-02-08 | Peters Jeffrey Stuart | Officer | A-Award | A | Employee Stock Option (right to buy) | 71,000 | 18.30 | 1.30M | 71,000 | — | ↗ |
| 2024-02-08 | Koenig Scott | Director / Officer | A-Award | A | Restricted Stock Unit | 95,000 | 0.00 | — | 95,000 | — | ↗ |
| 2024-02-08 | Karrels James | Officer | A-Award | A | Restricted Stock Unit | 30,000 | 0.00 | — | 30,000 | — | ↗ |
| 2024-02-08 | Eck Stephen L. | Officer | A-Award | A | Restricted Stock Unit | 33,500 | 0.00 | — | 33,500 | — | ↗ |
| 2024-02-08 | Cilinski Lynn | Officer | A-Award | A | Restricted Stock Unit | 17,000 | 0.00 | — | 17,000 | — | ↗ |
| 2024-02-08 | Bonvini Ezio | Officer | A-Award | A | Restricted Stock Unit | 33,500 | 0.00 | — | 33,500 | — | ↗ |
| 2024-02-07 | Bonvini Ezio | Officer | S-Sale | D | Common Stock | 3,334 | 18.00 | 60.0K | 71,334 | — | ↗ |
| 2024-02-05 | Peters Jeffrey Stuart | Officer | M-Exempt | D | Employee stock option (right to buy) | 21,875 | 10.15 | 222.0K | 48,125 | — | ↗ |
| 2024-02-01 | Bonvini Ezio | Officer | S-Sale | D | Common Stock | 13,316 | 15.00 | 199.7K | 74,668 | — | ↗ |
| 2024-01-19 | Bonvini Ezio | Officer | S-Sale | D | Common Stock | 13,316 | 12.00 | 159.8K | 87,984 | — | ↗ |
| 2023-12-20 | Bonvini Ezio | Officer | S-Sale | D | Common Stock | 18,880 | 10.08 | 190.3K | 101,300 | — | ↗ |
| 2023-10-02 | BIOTECH TARGET N V | 10% Owner | P-Purchase | A | Common Stock | 150,000 | 4.46 | 669.6K | 9,929,963 | — | ↗ |
| 2023-09-07 | BIOTECH TARGET N V | 10% Owner | P-Purchase | A | Common Stock | 200,000 | 5.26 | 1.05M | 9,779,963 | — | ↗ |
| 2023-08-30 | HURWITZ EDWARD | Director | P-Purchase | A | Common Stock | 15,000 | 4.91 | 73.7K | 33,074 | — | ↗ |
| 2023-05-31 | STUMP DAVID C | Director | A-Award | A | Restricted Stock Unit | 4,500 | 0.00 | — | 4,500 | — | ↗ |
| 2023-05-31 | SIEGEL JAY PHILIP | Director | A-Award | A | Stock Option (right to buy) | 21,490 | 4.67 | 100.4K | 21,490 | — | ↗ |
| 2023-05-31 | O'Brien Federica F. | Director | A-Award | A | Restricted Stock Unit | 4,500 | 0.00 | — | 4,500 | — | ↗ |
| 2023-05-31 | Liu Margaret | Director | A-Award | A | Restricted Stock Unit | 4,500 | 0.00 | — | 4,500 | — | ↗ |
| 2023-05-31 | Jackson Scott Thomas | Director | A-Award | A | Restricted Stock Unit | 4,500 | 0.00 | — | 4,500 | — | ↗ |
| 2023-05-31 | HURWITZ EDWARD | Director | A-Award | A | Restricted Stock Unit | 4,500 | 0.00 | — | 4,500 | — | ↗ |
| 2023-05-31 | HEIDEN WILLIAM K | Director | A-Award | A | Stock Option (right to buy) | 19,000 | 4.67 | 88.7K | 19,000 | — | ↗ |
| 2023-05-31 | Ferrante Karen Jean | Director | A-Award | A | Restricted Stock Unit | 4,500 | 0.00 | — | 4,500 | — | ↗ |
| 2023-05-31 | Chhabra Meenu | Director | A-Award | A | Stock Option (right to buy) | 19,000 | 4.67 | 88.7K | 19,000 | — | ↗ |
| 2023-03-10 | Peters Jeffrey Stuart | Officer | S-Sale | D | Common Stock | 5,372 | 6.03 | 32.4K | 0 | — | ↗ |
| 2023-02-22 | Peters Jeffrey Stuart | Officer | F-InKind | D | Common Stock | 3,378 | 6.55 | 22.1K | 5,372 | — | ↗ |
| 2023-02-22 | Bonvini Ezio | Officer | M-Exempt | D | Restricted Stock Unit | 9,375 | 0.00 | — | 0 | — | ↗ |
| 2023-02-15 | Spitznagel Thomas | Officer | A-Award | A | Restricted Stock Unit | 40,000 | 0.00 | — | 40,000 | — | ↗ |
| 2023-02-15 | Risser Eric Blasius | Officer | A-Award | A | Restricted Stock Unit | 50,000 | 0.00 | — | 50,000 | — | ↗ |
| 2023-02-15 | Peters Jeffrey Stuart | Officer | A-Award | A | Restricted Stock Unit | 40,000 | 0.00 | — | 40,000 | — | ↗ |
| 2023-02-15 | Koenig Scott | Director / Officer | A-Award | A | Restricted Stock Unit | 127,000 | 0.00 | — | 127,000 | — | ↗ |
| 2023-02-15 | Karrels James | Officer | A-Award | A | Restricted Stock Unit | 45,000 | 0.00 | — | 45,000 | — | ↗ |
| 2023-02-15 | Eck Stephen L. | Officer | A-Award | A | Restricted Stock Unit | 50,000 | 0.00 | — | 50,000 | — | ↗ |
| 2023-02-15 | Cilinski Lynn | Officer | A-Award | A | Restricted Stock Unit | 20,000 | 0.00 | — | 20,000 | — | ↗ |
| 2023-02-15 | Bonvini Ezio | Officer | A-Award | A | Employee stock option (right to buy) | 200,000 | 4.82 | 964.0K | 200,000 | — | ↗ |
| 2023-02-14 | BIOTECH TARGET N V | 10% Owner | P-Purchase | A | Common Stock | 500,000 | 5.07 | 2.53M | 9,579,963 | — | ↗ |
| 2023-01-19 | BIOTECH TARGET N V | Director | P-Purchase | A | Common Stock | 150,000 | 5.30 | 794.9K | 9,079,963 | — | ↗ |
| 2023-01-03 | Liu Margaret | Director | A-Award | A | Stock Option (right to buy) | 36,000 | 0.00 | — | 36,000 | — | ↗ |
| 2023-01-03 | Chhabra Meenu | Director | A-Award | A | Stock Option (right to buy) | 36,000 | 0.00 | — | 36,000 | — | ↗ |
| 2022-12-27 | BIOTECH TARGET N V | Director | P-Purchase | A | Common Stock | 200,000 | 5.61 | 1.12M | 8,929,963 | — | ↗ |
| 2022-12-23 | BIOTECH TARGET N V | Director | P-Purchase | A | Common Stock | 200,000 | 5.88 | 1.18M | 8,729,963 | — | ↗ |
| 2022-11-22 | BIOTECH TARGET N V | Director | P-Purchase | A | Common Stock | 300,000 | 5.96 | 1.79M | 8,529,963 | — | ↗ |
| 2022-10-28 | Risser Eric Blasius | Officer | M-Exempt | A | Common Stock | 8,500 | 1.51 | 12.8K | 53,468 | — | ↗ |
| 2022-10-24 | BIOTECH TARGET N V | Director | P-Purchase | A | Common Stock | 250,000 | 4.36 | 1.09M | 8,229,963 | — | ↗ |
| 2022-10-21 | BIOTECH TARGET N V | Director | P-Purchase | A | Common Stock | 250,000 | 4.63 | 1.16M | 7,979,963 | — | ↗ |
| 2022-10-20 | BIOTECH TARGET N V | Director | P-Purchase | A | Common Stock | 285,977 | 4.00 | 1.14M | 7,729,963 | — | ↗ |
| 2022-10-19 | BIOTECH TARGET N V | Director | P-Purchase | A | Common Stock | 168,422 | 3.70 | 623.9K | 7,443,986 | — | ↗ |
| 2022-06-15 | Karrels James | Officer | P-Purchase | A | Common Stock | 40,000 | 2.47 | 98.8K | 191,776 | — | ↗ |
| 2022-05-23 | HEIDEN WILLIAM K | Director | A-Award | A | Stock Option (right to buy) | 36,000 | 0.00 | — | 36,000 | — | ↗ |
| 2022-05-19 | STUMP DAVID C | Director | A-Award | A | Stock Option (right to buy) | 18,000 | 0.00 | — | 18,000 | — | ↗ |
| 2022-05-19 | SIEGEL JAY PHILIP | Director | A-Award | A | Stock Option (right to buy) | 18,000 | 3.90 | 70.2K | 18,000 | — | ↗ |
| 2022-05-19 | O'Brien Federica F. | Director | A-Award | A | Stock Option (right to buy) | 24,080 | 0.00 | — | 24,080 | — | ↗ |
| 2022-05-19 | Jackson Scott Thomas | Director | A-Award | A | Stock Option (right to buy) | 18,000 | 0.00 | — | 18,000 | — | ↗ |
| 2022-05-19 | HURWITZ EDWARD | Director | A-Award | A | Stock Option (right to buy) | 18,000 | 3.90 | 70.2K | 18,000 | — | ↗ |
| 2022-05-19 | Ferrante Karen Jean | Director | A-Award | A | Stock Option (right to buy) | 18,000 | 3.90 | 70.2K | 18,000 | — | ↗ |
| 2022-05-16 | Koenig Scott | Officer | M-Exempt | A | Common Stock | 53,265 | 1.51 | 80.4K | 1,049,636 | — | ↗ |
| 2022-05-14 | Bonvini Ezio | Officer | F-InKind | D | Common Stock | 1,666 | 4.16 | 6.9K | 114,424 | — | ↗ |
| 2022-03-28 | Karrels James | Officer | M-Exempt | A | Common Stock | 8,316 | 1.51 | 12.6K | 151,776 | — | ↗ |
| 2022-03-04 | Risser Eric Blasius | Officer | M-Exempt | D | Employee stock option (right to buy) | 500 | 0.00 | — | 0 | — | ↗ |
| 2022-02-22 | Spitznagel Thomas | Officer | A-Award | A | Employee stock option (right to buy) | 140,000 | 10.15 | 1.42M | 140,000 | — | ↗ |
| 2022-02-22 | Risser Eric Blasius | Officer | A-Award | A | Employee stock option (right to buy) | 170,000 | 10.15 | 1.73M | 170,000 | — | ↗ |
| 2022-02-22 | Peters Jeffrey Stuart | Officer | A-Award | A | Restricted Stock Unit | 35,000 | 0.00 | — | 35,000 | — | ↗ |
| 2022-02-22 | Koenig Scott | Director / Officer | A-Award | A | Employee stock option (right to buy) | 480,000 | 10.15 | 4.87M | 480,000 | — | ↗ |
| 2022-02-22 | Karrels James | Officer | A-Award | A | Employee stock option (right to buy) | 140,000 | 10.15 | 1.42M | 140,000 | — | ↗ |
| 2022-02-22 | Eck Stephen L. | Officer | A-Award | A | Employee stock option (right to buy) | 150,000 | 10.15 | 1.52M | 150,000 | — | ↗ |
| 2022-02-22 | Cilinski Lynn | Officer | A-Award | A | Employee stock option (right to buy) | 63,400 | 10.15 | 643.5K | 63,400 | — | ↗ |
| 2022-02-22 | Bonvini Ezio | Officer | A-Award | A | Restricted Stock Unit | 37,500 | 0.00 | — | 37,500 | — | ↗ |
| 2021-11-19 | BIOTECH TARGET N V | 10% Owner | P-Purchase | A | Common Stock | 200,000 | 18.50 | 3.70M | 7,275,564 | — | ↗ |
| 2021-11-16 | Bonvini Ezio | Officer | M-Exempt | A | Common Stock | 2,540 | 16.00 | 40.6K | 111,090 | — | ↗ |
| 2021-09-29 | BIOTECH TARGET N V | 10% Owner | P-Purchase | A | Common Stock | 100,000 | 20.47 | 2.05M | 7,075,564 | — | ↗ |
| 2021-09-28 | BIOTECH TARGET N V | 10% Owner | P-Purchase | A | Common Stock | 100,000 | 20.64 | 2.06M | 6,975,564 | — | ↗ |
| 2021-09-17 | BIOTECH TARGET N V | 10% Owner | P-Purchase | A | Common Stock | 200,000 | 19.93 | 3.99M | 6,875,564 | — | ↗ |
| 2021-09-16 | BIOTECH TARGET N V | 10% Owner | P-Purchase | A | Common Stock | 400,000 | 20.94 | 8.38M | 6,675,564 | — | ↗ |
| 2021-07-16 | Spitznagel Thomas | Officer | M-Exempt | D | Employee stock option (right to buy) | 5,000 | 7.51 | 37.6K | 37,147 | — | ↗ |
| 2021-06-24 | Bonvini Ezio | Officer | M-Exempt | D | Employee stock option (right to buy) | 4,221 | 20.53 | 86.7K | 63,279 | — | ↗ |
| 2021-06-21 | BIOTECH TARGET N V | 10% Owner | P-Purchase | A | Common Stock | 75,000 | 21.74 | 1.63M | 6,275,564 | — | ↗ |
| 2021-06-16 | BIOTECH TARGET N V | 10% Owner | P-Purchase | A | Common Stock | 100,000 | 21.04 | 2.10M | 6,200,564 | — | ↗ |
| 2021-06-15 | BIOTECH TARGET N V | 10% Owner | P-Purchase | A | Common Stock | 75,000 | 20.53 | 1.54M | 6,100,564 | — | ↗ |
| 2021-06-09 | BIOTECH TARGET N V | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 6,025,564 | — | ↗ |
| 2021-05-14 | Bonvini Ezio | Officer | M-Exempt | A | Common Stock | 5,000 | 0.00 | — | 84,890 | — | ↗ |
| 2021-05-13 | STUMP DAVID C | Director | A-Award | A | Stock Option (right to buy) | 15,000 | 28.88 | 433.2K | 15,000 | — | ↗ |
| 2021-05-13 | SIEGEL JAY PHILIP | Director | A-Award | A | Stock Option (right to buy) | 15,000 | 28.88 | 433.2K | 15,000 | — | ↗ |
| 2021-05-13 | O'Brien Federica F. | Director | A-Award | A | Stock Option (right to buy) | 15,000 | 28.88 | 433.2K | 15,000 | — | ↗ |
| 2021-05-13 | Jackson Scott Thomas | Director | A-Award | A | Stock Option (right to buy) | 15,000 | 28.88 | 433.2K | 15,000 | — | ↗ |
| 2021-05-13 | HURWITZ EDWARD | Director | A-Award | A | Stock Option (right to buy) | 15,000 | 28.88 | 433.2K | 15,000 | — | ↗ |
| 2021-05-13 | Galbraith Kenneth | Director | A-Award | A | Stock Option (right to buy) | 15,000 | 28.88 | 433.2K | 15,000 | — | ↗ |
| 2021-05-13 | Ferrante Karen Jean | Director | A-Award | A | Stock Option (right to buy) | 15,000 | 28.88 | 433.2K | 15,000 | — | ↗ |
| 2021-05-13 | Costa Paulo F | Director | A-Award | A | Stock Option (right to buy) | 15,000 | 28.88 | 433.2K | 15,000 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-242.8K
Shares Outstanding
63.56M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Eric Risser President, Chief Executive Officer and Director | 561.6K | 150.0K | 52.0K | 1.05M | 251.9K | 14.0K | 2.08M | 52.98% | ↗ |
| 2 | 2025 | Ezio Bonvini Senior Vice President, Research and Chief Scientific Officer | 533.2K | 150.0K | 54.6K | 288.0K | 184.2K | 14.0K | 1.22M | 27.99% | ↗ |
| 3 | 2025 | James Karrels Senior Vice President and Chief Financial Officer | 506.5K | 150.0K | 49.4K | 254.3K | 175.0K | 14.0K | 1.15M | 26.42% | ↗ |
| 4 | 2025 | Scott Koenig, M.D., Ph.D. Former Chief Executive Officer and current Director | 477.1K | — | — | — | — | 475.8K | 953.0K | 0.00% | ↗ |
| 5 | 2024 | Scott Koenig, M.D., Ph.D. Former Chief Executive Officer and current Director | 734.0K | — | 1.74M | 3.57M | 342.5K | 13.8K | 6.40M | 82.97% | ↗ |
| 6 | 2024 | Scott Koenig, M.D., Ph.D. President, Chief Executive Officer and Director | 734.0K | — | 1.74M | 3.57M | 342.5K | 13.8K | 6.40M | 82.97% | ↗ |
| 7 | 2024 | Stephen Eck, M.D., Ph.D. Senior Vice President, Clinical Development and Chief Medical Officer | 542.8K | — | 613.1K | 1.30M | 178.7K | 13.8K | 2.65M | 72.21% | ↗ |
| 8 | 2024 | James Karrels Senior Vice President and Chief Financial Officer | 491.1K | — | 549.0K | 1.15M | 158.6K | 13.8K | 2.37M | 71.95% | ↗ |
| 9 | 2024 | James Karrels Senior Vice President, Chief Financial Officer and Corporate Secretary | 491.1K | — | 549.0K | 1.15M | 158.6K | 13.8K | 2.37M | 71.95% | ↗ |
| 10 | 2023 | Scott Koenig, M.D., Ph.D. President, Chief Executive Officer and Director | 704.9K | — | 612.1K | 1.89M | 481.4K | 13.2K | 3.71M | 67.63% | ↗ |
| 11 | 2023 | Stephen Eck, M.D., Ph.D. Senior Vice President, Clinical Development and Chief Medical Officer | 521.8K | — | 241.0K | 742.8K | 231.8K | 13.2K | 1.75M | 56.20% | ↗ |
| 12 | 2023 | James Karrels Senior Vice President, Chief Financial Officer and Corporate Secretary | 471.1K | — | 216.9K | 668.5K | 209.0K | 13.2K | 1.58M | 56.08% | ↗ |
| 13 | 2022 | Scott Koenig, M.D., Ph.D. President, Chief Executive Officer and Director | 673.4K | — | — | 3.57M | 373.7K | 12.2K | 4.63M | 77.11% | ↗ |
| 14 | 2022 | Eric Risser Chief Operating Officer | 460.8K | — | — | 1.26M | 178.4K | 12.2K | 1.92M | 65.99% | ↗ |
| 15 | 2022 | James Karrels Senior Vice President, Chief Financial Officer and Corporate Secretary | 447.3K | — | — | 1.04M | 167.3K | 12.2K | 1.67M | 62.41% | ↗ |
| 16 | 2021 | Scott Koenig, M.D., Ph.D. President, Chief Executive Officer and Director | 651.1K | — | — | 3.91M | 294.3K | 8.7K | 4.87M | 80.40% | ↗ |
| 17 | 2021 | Ezio Bonvini, M.D. Senior Vice President, Research and Chief Scientific Officer | 462.3K | — | — | 1.68M | 141.2K | 8.7K | 2.29M | 73.26% | ↗ |
| 18 | 2021 | James Karrels Senior Vice President, Chief Financial Officer and Corporate Secretary | 431.9K | — | — | 1.33M | 137.3K | 8.7K | 1.91M | 69.68% | ↗ |
| 19 | 2021 | Eric Risser Chief Operating Officer | 428.0K | — | — | 1.33M | 135.3K | 8.7K | 1.90M | 69.90% | ↗ |
| 20 | 2021 | Thomas Spitznagel, Ph.D. Senior Vice President, Technical Operations | 410.0K | — | — | 1.33M | 132.3K | 8.7K | 1.88M | 70.68% | ↗ |
| 21 | 2020 | Stephen Eck, M.D. Senior Vice President, Clinical Development and Chief Medical Officer | 236.3K | — | — | 4.79M | 97.9K | 7.1K | 5.13M | 93.35% | ↗ |
| 22 | 2020 | Scott Koenig, M.D., Ph.D. President, Chief Executive Officer and Director | 655.9K | — | — | 2.07M | 381.0K | 8.6K | 3.11M | 66.40% | ↗ |
| 23 | 2020 | Ezio Bonvini, M.D. Senior Vice President, Research and Chief Scientific Officer | 465.7K | — | 249.7K | 712.4K | 184.0K | 8.6K | 1.62M | 59.38% | ↗ |
| 24 | 2020 | James Karrels Senior Vice President, Chief Financial Officer and Corporate Secretary | 431.5K | — | — | 641.1K | 173.8K | 8.6K | 1.25M | 51.09% | ↗ |
| 25 | 2020 | Eric Risser Chief Operating Officer | 431.1K | — | — | 641.1K | 170.3K | 8.6K | 1.25M | 51.25% | ↗ |
| 26 | 2020 | Eric Risser Senior Vice President, Business Development and Portfolio Management and Chief Business Officer | 431.1K | — | — | 641.1K | 170.3K | 8.6K | 1.25M | 51.25% | ↗ |
| 27 | 2019 | Scott Koenig, M.D., Ph.D. President, Chief Executive Officer and Director | 590.0K | — | — | 3.82M | 307.0K | 8.4K | 4.72M | 80.83% | ↗ |
| 28 | 2019 | Jon Wigginton, M.D. Senior Vice President, Clinical Development and Chief Medical Officer | 453.5K | — | — | 1.32M | 163.4K | 3.8K | 1.94M | 68.05% | ↗ |
| 29 | 2019 | Ezio Bonvini, M.D. Senior Vice President, Research and Chief Scientific Officer | 419.0K | — | — | 1.32M | 147.8K | 8.4K | 1.90M | 69.68% | ↗ |
| 30 | 2019 | James Karrels Senior Vice President, Chief Financial Officer and Corporate Secretary | 387.6K | — | — | 1.25M | 137.3K | 8.4K | 1.78M | 70.07% | ↗ |
| 31 | 2019 | Eric Risser Senior Vice President, Business Development and Portfolio Management and Chief Business Officer | 387.8K | — | — | 1.25M | 135.2K | 8.4K | 1.78M | 70.14% | ↗ |
| 32 | 2019 | Eric Risser Chief Operating Officer | 387.8K | — | — | 1.25M | 135.2K | 8.4K | 1.78M | 70.14% | ↗ |
| 33 | 2018 | Scott Koenig, M.D., Ph.D. President, Chief Executive Officer and Director | 598.5K | — | — | 4.29M | 309.4K | 8.3K | 5.21M | 82.40% | ↗ |
| 34 | 2018 | Jon Wigginton, M.D. Senior Vice President, Clinical Development and Chief Medical Officer | 460.0K | — | — | 1.33M | 173.3K | 8.3K | 1.98M | 67.53% | ↗ |
| 35 | 2018 | Ezio Bonvini, M.D. Senior Vice President, Research and Chief Scientific Officer | 425.0K | — | — | 1.33M | 160.1K | 8.3K | 1.93M | 69.22% | ↗ |
| 36 | 2018 | Eric Risser Senior Vice President, Business Development and Portfolio Management and Chief Business Officer | 393.4K | — | — | 1.33M | 148.5K | 8.3K | 1.88M | 70.81% | ↗ |
| 37 | 2018 | James Karrels Senior Vice President, Chief Financial Officer and Corporate Secretary | 390.0K | — | — | 1.33M | 148.5K | 8.3K | 1.88M | 70.94% | ↗ |
| 38 | 2017 | Scott Koenig, M.D., Ph.D. President, Chief Executive Officer and Director | 554.3K | — | — | 2.57M | 350.6K | 8.1K | 3.48M | 73.75% | ↗ |
| 39 | 2017 | Jon Wigginton, M.D. Senior Vice President, Clinical Development and Chief Medical Officer | 445.1K | — | — | 865.7K | 197.6K | 8.1K | 1.52M | 57.09% | ↗ |
| 40 | 2017 | Ezio Bonvini, M.D. Senior Vice President, Research and Chief Scientific Officer | 404.7K | — | — | 865.7K | 179.7K | 8.1K | 1.46M | 59.37% | ↗ |
| 41 | 2017 | Eric Risser Senior Vice President, Business Development and Portfolio Management and Chief Business Officer | 374.7K | — | — | 705.4K | 176.8K | 8.1K | 1.26M | 55.76% | ↗ |
| 42 | 2017 | James Karrels Senior Vice President, Chief Financial Officer and Corporate Secretary | 360.0K | — | — | 705.4K | 160.7K | 8.1K | 1.23M | 57.15% | ↗ |
| 43 | 2016 | Jon Wigginton, M.D. Senior Vice President, Clinical Development and Chief Medical Officer | 423.4K | — | 458.4K | — | 134.6K | 8.0K | 1.02M | 44.75% | ↗ |
| 44 | 2016 | Ezio Bonvini, M.D. Senior Vice President, Research and Chief Scientific Officer | 369.6K | — | — | 526.1K | 115.1K | 8.0K | 1.02M | 51.64% | ↗ |
| 45 | 2016 | Ezio Bonvini, M.D. Senior Vice President, Research and Chief Scientific | 369.6K | — | — | 526.1K | 115.1K | 8.0K | 1.02M | 51.64% | ↗ |
| 46 | 2016 | Eric Risser Senior Vice President, Business Development | 350.2K | — | — | 438.5K | 116.4K | 8.0K | 913.0K | 48.03% | ↗ |
| 47 | 2016 | Eric Risser Senior Vice President, Business Development and Portfolio Management and Chief Business Officer | 350.2K | — | — | 438.5K | 116.4K | 8.0K | 913.0K | 48.03% | ↗ |
| 48 | 2016 | Scott Koenig, M.D., Ph.D. President, Chief Executive Officer and Director | 535.6K | — | — | — | 240.0K | 8.0K | 783.6K | 0.00% | ↗ |
| 49 | 2016 | James Karrels Senior Vice President, Chief Financial Officer and Corporate Secretary | 344.4K | — | — | — | 105.1K | 8.0K | 457.5K | 0.00% | ↗ |
| 50 | 2015 | Scott Koenig, M.D., Ph.D. President, Chief Executive Officer and Director | 523.0K | — | — | 3.11M | 266.0K | 4.0K | 3.91M | 79.70% | ↗ |
| 51 | 2015 | Jon Wigginton, M.D. Senior Vice President, Clinical Development | 380.8K | — | — | 1.14M | 127.1K | 4.0K | 1.65M | 69.04% | ↗ |
| 52 | 2015 | Jon Wigginton, M.D. Senior Vice President, Clinical Development and Chief Medical Officer | 380.8K | — | — | — | 127.1K | 4.0K | 1.65M | 0.00% | ↗ |
| 53 | 2015 | Ezio Bonvini, M.D. Senior Vice President, Research and Chief Scientific Officer | 353.0K | — | — | 1.14M | 117.4K | 4.0K | 1.62M | 70.64% | ↗ |
| 54 | 2015 | Ezio Bonvini, M.D. Senior Vice President, Research and Chief Scientific | 353.0K | — | — | 1.14M | 117.4K | 4.0K | 1.62M | 70.64% | ↗ |
| 55 | 2015 | Ezio Bonvini, M.D. Senior Vice President, Research | 353.0K | — | — | 1.14M | 117.4K | 4.0K | 1.62M | 70.64% | ↗ |
| 56 | 2015 | Atul Saran Senior Vice President and General Counsel | 357.7K | — | — | 933.9K | 119.7K | 94.0K | 1.51M | 62.04% | ↗ |
| 57 | 2015 | Eric Risser Senior Vice President, Business Development and Portfolio Management and Chief Business Officer | 336.4K | — | — | 933.9K | 110.0K | 4.0K | 1.38M | 67.46% | ↗ |
| 58 | 2015 | Eric Risser Senior Vice President, Business Development | 336.5K | — | — | 933.9K | 110.0K | 4.0K | 1.38M | 67.46% | ↗ |
| 59 | 2015 | James Karrels Senior Vice President, Chief Financial Officer and Corporate Secretary | 336.5K | — | — | — | 107.6K | 4.0K | 1.38M | 0.00% | ↗ |
| 60 | 2014 | Scott Koenig, M.D., Ph.D. President, Chief Executive Officer and Director | 466.5K | — | — | 2.59M | 280.0K | 3.9K | 3.34M | 77.55% | ↗ |
| 61 | 2014 | Atul Saran Senior Vice President and General Counsel | 228.9K | 50.0K | 469.6K | 1.73M | 88.0K | 3.9K | 2.57M | 85.59% | ↗ |
| 62 | 2014 | Ezio Bonvini, M.D. Senior Vice President, Research | 328.0K | — | — | 925.8K | 130.0K | 3.9K | 1.39M | 66.71% | ↗ |
| 63 | 2014 | Ezio Bonvini, M.D. Senior Vice President, Research and Chief Scientific | 328.0K | — | — | 925.8K | 130.0K | 3.9K | 1.39M | 66.71% | ↗ |
| 64 | 2014 | Eric Risser Senior Vice President, Business Development | 301.4K | — | — | 925.8K | 121.0K | 3.9K | 1.35M | 68.47% | ↗ |
| 65 | 2014 | Jon Wigginton, M.D. Senior Vice President, Clinical Development | 369.7K | — | — | 740.7K | 131.0K | 3.9K | 1.25M | 59.48% | ↗ |
| 66 | 2014 | Jon Wigginton, M.D. Senior Vice President, Clinical Development and Chief Medical Officer | 369.7K | — | — | 740.7K | 131.0K | 3.9K | 1.25M | 59.48% | ↗ |
| 67 | 2014 | James Karrels Senior Vice President, Chief Financial Officer and Corporate Secretary | 313.8K | — | — | 740.7K | 115.0K | 3.9K | 1.17M | 63.12% | ↗ |
| 68 | 2013 | Scott Koenig, M.D., Ph.D. President, Chief Executive Officer and Director | 456.1K | — | — | 2.52M | 275.0K | 3.8K | 3.26M | 77.43% | ↗ |
| 69 | 2013 | Jon Wigginton, M.D. Senior Vice President, Clinical Development | 148.6K | 237.5K | — | 801.1K | 106.2K | — | 1.29M | 61.94% | ↗ |
| 70 | 2013 | James Karrels Senior Vice President, Chief Financial Officer and Corporate Secretary | 306.7K | — | — | 800.8K | 123.3K | 3.8K | 1.23M | 64.86% | ↗ |
| 71 | 2013 | Ezio Bonvini, M.D. Senior Vice President, Research | 310.4K | — | — | 430.5K | 108.1K | 3.8K | 852.8K | 50.48% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Eric Blasius Risser | Chief Executive Officer, President & Director | 977.5K | male |
| Ezio Bonvini | Senior Vice President of Research & Chief Scientific Officer | 881.4K | — |
| James Karrels | Senior Vice President, Chief Financial Officer & Corporate Secretary | 845.5K | male |
| Thomas Spitznagel | Senior Vice President of Technical Operations | 551.0K | — |
| Steve Harig | Senior Vice President of Human Resources | — | male |
| Harish Krishnaswamy | Senior Vice President of Business Development & Portfolio Planning | — | male |
| Frank George Perabo FEBU | Vice President & Interim Head of Clinical Development | — | — |
| Beth Smith | Vice President, Controller & Treasurer | — | female |
| Jeffrey Stuart Peters | Senior VP, Corporate Secretary, General Counsel & Corporate Compliance Officer | — | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for MGNX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
